RightAnswer Knowledge Solutions Search Results for 53-19-0

New Search  |  Search Results (53-19-0 )  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • Personal Protection
  • Physical Hazards/Corrective Response Actions
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

HAZARDTEXT™ Documentshelp
MEDITEXT® Documentshelp

All Other Data Sources:

CCRIS Documentshelp
DART Documentshelp
ECOTOX Documentshelp
GENE-TOX Documentshelp
HSDB® Data Bankhelp
LOLI® Listingshelp
RTECS® Registryhelp
TERIS Documentshelp
MSDSonline®help

ChemID External Links:

Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for 53-19-0 :


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. USES: Mitotane is indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.
  1. PHARMACOLOGY: The exact mechanism of action of mitotane is not known. It does cause cytotoxic atrophy of the adrenal cells which is associated with unresponsiveness to ACTH administration. In addition, mitotane, in an independent manner, appears to alter the pattern of corticoid metabolism. Mitotane reduced the excretion of 17-hydroxycorticosteroids without concomitant reductions in plasma cortisol or cortisol secretion rates, as well as, increased the formation of 6-beta-hydroxyl cortisol.
  1. EPIDEMIOLOGY: Overdose is rare.
  1. WITH THERAPEUTIC USE
    1. COMMON; about 80%: Anorexia, nausea, vomiting, anorexia, diarrhea; 15% to 40%: CNS depression (eg; lethargy, somnolence, dizziness or vertigo), and skin rashes. INFREQUENT: Ocular effects (eg, blurred vision, diplopia, lens opacity, and retinopathy), hematuria, hemorrhagic cystitis, albuminuria, hypertension, orthostatic hypotension, flushing, and hyperpyrexia.
  1. WITH POISONING/EXPOSURE
    1. Overdose data are limited. Overdose effects are anticipated to be an extension of adverse effects observed following therapeutic doses.
© 2011-2025 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.